Hematology

MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia

Wednesday, June 3, 2020 - 9:05pm

AML is a hematological malignancy characterized by differentiation arrest and uncontrolled clonal proliferation of neoplastic precursors that prevent normal bone marrow hematopoiesis.

Key Points: 
  • AML is a hematological malignancy characterized by differentiation arrest and uncontrolled clonal proliferation of neoplastic precursors that prevent normal bone marrow hematopoiesis.
  • The primary mechanism of action of flotetuzumab is believed to be its ability to redirect T lymphocytes to kill CD123-expressing cells.
  • The study will be conducted as a continuation of the ongoing Phase 1/2 study (NCT02152956; to be updated).
  • MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer.

Local Blood Center Offers Consistent Donation Site for Florence Blood Donors

Wednesday, June 3, 2020 - 2:12pm

The Blood Connection (TBC), a local non-profit, community blood center is now offering blood donors in Florence, SC a more permanent location to donate blood.

Key Points: 
  • The Blood Connection (TBC), a local non-profit, community blood center is now offering blood donors in Florence, SC a more permanent location to donate blood.
  • A blood mobile will be stationed outside of the future TBC Florence Donation Center at 1617 S Irby Street in Florence starting June 1, Monday through Friday from 11 a.m. to 4 p.m.
  • The blood mobile will be available until TBC opens the donation center later this year.
  • All donors who complete a blood donation will receive COVID-19 antibody testing at no cost.

InventHelp Inventor Develops Accessory to Protect a Baby's Knees while Crawling (TPA-2726)

Tuesday, June 2, 2020 - 4:00pm

The invention provides an effective way to protect a baby's knees while crawling on the floor.

Key Points: 
  • The invention provides an effective way to protect a baby's knees while crawling on the floor.
  • In doing so, it could help to prevent bruises, carpet burns and abrasions.
  • As a result, it enhances safety and comfort and it provides added peace of mind.
  • The invention features a protective design that is convenient and easy to use so it is ideal for infants and toddlers.

2020 Global Non-Hodgkin Lymphoma Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Tuesday, June 2, 2020 - 10:41am

The "Global Non-Hodgkin Lymphoma Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Non-Hodgkin Lymphoma Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Non-Hodgkin Lymphoma market.
  • It covers emerging therapies for Non-Hodgkin Lymphoma in active clinical development stages including early and late-stage clinical trials.
  • The report provides Non-Hodgkin Lymphoma pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Endexx Sponsors 5th Annual Sophie's Day Golf Tournament benefiting the Leukemia and Lymphoma Society

Monday, June 1, 2020 - 1:30pm

Endexx is proud to sponsor the annual benefit sponsoring the Leukemia and Lymphoma Society and research into rare childhood cancer diseases.

Key Points: 
  • Endexx is proud to sponsor the annual benefit sponsoring the Leukemia and Lymphoma Society and research into rare childhood cancer diseases.
  • The Company is sponsoring the 10th hole and will be offering its topical CBD Unlimited products for use and sale.
  • The products have proven to support golf patrons in their pursuit of a more comfortable golf experience including reduced fatigue and soreness.
  • Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets.

Vitalant Begins Testing All Blood Donations for Antibodies to COVID-19

Monday, June 1, 2020 - 11:00am

SCOTTSDALE, Ariz., June 1, 2020 /PRNewswire/ -- Today, Vitalant became the first national blood bank to test all blood donations for antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.

Key Points: 
  • SCOTTSDALE, Ariz., June 1, 2020 /PRNewswire/ -- Today, Vitalant became the first national blood bank to test all blood donations for antibodies to SARS-CoV-2, the coronavirus that causes COVID-19.
  • The nation's largest independent, nonprofit blood collector is providing the test results to donors who complete successful blood donations, which are critically needed now.
  • The antibody tests are part of a full panel of tests that Vitalant performs on successful blood donations.
  • In addition to Vitalant providing lifesaving blood to patients in need, Vitalant Research Institute is leading several research initiatives related to SARS-CoV-2 antibodies.

Global Blood Transfusion Devices Market Analysis 2020-2025 - The Pathogen Reduction System is Expected to Witness Healthy Growth - ResearchAndMarkets.com

Friday, May 29, 2020 - 11:58am

The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Transfusion Devices Market - Growth, Trends, and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • The rise in the number of blood disorders, such as anemia, leukopenia, erythrocytosis, leukocytosis, and thrombocytosis is also boosting the blood transfusion market.
  • The pathogen reduction system segment of the blood transfusion market is believed to witness a healthy growrh over the forecast period.
  • Companies like Immucor Inc., Becton Dickinson, B. Braun, Terumo Corporation, and Grifols SA., hold a significant share in the blood transfusion market.

Global Hodgkin Lymphoma Clinical Trial Pipeline Highlights - 2020 - ResearchAndMarkets.com

Friday, May 29, 2020 - 11:45am

The "Global Hodgkin Lymphoma Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hodgkin Lymphoma Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Hodgkin Lymphoma market.
  • It covers emerging therapies for Hodgkin Lymphoma in active clinical development stages including early and late-stage clinical trials.
  • The report provides Hodgkin Lymphoma pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Bio Products Laboratory Announces Launch of ALBUMINEX® 5% and ALBUMINEX® 25% With Supply Immediately Available in the United States

Wednesday, May 27, 2020 - 7:29pm

Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.

Key Points: 
  • Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.
  • No cases of transmission of viral diseases or CJD have ever been identified for ALBUMINEX 5% or ALBUMINEX 25%.
  • BPL USA is part of a global company, Bio Products Laboratory, which boasts a vibrant 60-year heritage in plasma research, technology, and manufacturing.
  • View original content to download multimedia: http://www.prnewswire.com/news-releases/bio-products-laboratory-announce...
    SOURCE Bio Products Laboratory USA Inc.

Leading Thrombosis Specialists Issue Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19

Wednesday, May 27, 2020 - 3:08pm

The recommendations are published in a new paper, titled "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," published on May 27, 2020 in the Journal of Thrombosis and Haemostasis (JTH).

Key Points: 
  • The recommendations are published in a new paper, titled "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," published on May 27, 2020 in the Journal of Thrombosis and Haemostasis (JTH).
  • The peer-reviewed paper outlines new practical guidance on the prevention and treatment of VTE in hospitalized patients with COVID-19.
  • The recommendations were developed by a multidisciplinary panel of thrombosis experts as a response to widespread clinical reports of unusual, difficult-to-control clotting in COVID-19 patients.
  • For more information on the paper, "Clinical Guidance on the Diagnosis, Prevention and Treatment of Venous Thromboembolism in Hospitalized Patients with COVID-19," visit https://onlinelibrary.wiley.com/doi/abs/10.111/jth.14929.